Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial

Trial Status: active

This phase III trial compares the addition of chemotherapy to usual treatment (ovarian function suppression plus hormonal therapy) to usual treatment alone in treating premenopausal estrogen receptor (ER)-positive/HER2-negative breast cancer patients who are at high risk of their cancer returning. One of the likely benefits of chemotherapy is that it can stop the ovaries from releasing eggs and hormones in women who are premenopausal. This study may help researchers determine if adding chemotherapy to ovarian suppression and hormonal therapy has similar effectiveness to ovarian suppression and hormonal therapy alone in preventing cancer from returning.